Summary

Results of a double-blind, randomized, placebo-controlled, parallel-group trial do not support the routine use of metformin in nondiabetic patients after ST-segment elevation myocardial infarction (STEMI) for the purpose of preserving myocardial function. Findings of the Metformin to Reduce Heart Failure After Myocardial Infarction trial [GIPS-III; Lexis CPH et al. JAMA 2014] are discussed in this article.